CoChat

Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies

Open access
Rees, Karen, Stowe, Rebecca, Patel, Smitaa, Ives, Natalie, Breen, Kieran, Clarke, Carl E, Ben-Shlomo, Yoav · 2011 · Cochrane Database of Systematic Reviews
Cited by 101

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Neuroinflammation may play a key role in the neurodegeneration associated with Parkinson's disease (PD). Non-steroidal anti-inflammatory drugs (NSAIDs) may be beneficial in the primary and secondary prevention of PD. OBJECTIVES: 1) Do NSAIDs prevent the onset of PD?2) Are NSAIDs neuroprotective in PD - do they slow the progression of disease once PD is established?3) What are the adverse effects of taking NSAIDs in PD? SEARCH METHODS: We searched electronic databases, including trial registers, complemented with handsearching of conference proceedings and citation searching on key articles. All searching was updated in May 2011. We contacted authors to provide additional information where necessary. SELECTION CRITERIA: For the primary prevention review, we sought primary prevention trials and observational studies (cohort and case-control studies). Participants were free of PD when exposure to NSAIDs was assessed. For the secondary prevention review, we sought clinical trials in patients with a well-defined definition of PD. Two people independently selected studies for inclusion using predetermined criteria. DATA COLLECTION AND ANALYSIS: Two review authors abstracted data from the source papers and assessed methodological quality independently. No studies met the inclusion criteria for the secondary prevention review. For the primary prevention review only observational studies were found. We combined data where appropriate using the inverse variance method. We assessed methodological quality using the Newcastle Ottawa Scales and by examining the period of exposure assessed prior to PD onset (or the index date in controls). MAIN RESULTS: Fourteen observational studies met the inclusion criteria for the primary prevention review (five cohort, nine case-control studies). Exposure to any NSAIDs or aspirin had no effect on the risk of developing PD. Exposure to non-aspirin NSAIDs reduced the risk of developing PD by 13% (effect estimate 0.87 (95% CI 0.73 to 1.04 - random-effects model), but this did not reach statistical significance. We found similar results for the most robust studies. Ibuprofen in isolation was examined in four studies and was associated with a 27% reduction in risk (effect estimate 0.73, 95% CI 0.63 to 0.85). There was a lack of information on adverse effects. AUTHORS' CONCLUSIONS: There is currently no evidence for the use of NSAIDs in the secondary prevention of PD. Non-aspirin NSAIDs, particularly ibuprofen, may reduce the risk of developing PD. However, little is known of the effects of other individual drugs and at present no recommendations can be made regarding their use in primary prevention.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/14651858.cd008454.pub2

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 45

  1. Bornebroek, 2007, Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease, Neuroepidemiology, 28, 193, 10.1159/000108110 · DOI · Paper page
  2. Bower-JH, 2006, Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: a case-control study, Neurology, 67, 494, 10.1212/01.wnl.0000227906.99570.cc · DOI · Paper page
  3. Chen, 2003, Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease, Archives of Neurology, 60, 1059, 10.1001/archneur.60.8.1059 · DOI · Paper page
  4. Chen, 2005, Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease, Annals of Neurology, 58, 963, 10.1002/ana.20682 · DOI · Paper page
  5. Driver, 2011, Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case control study, British Medical Journal, 342, d198, 10.1136/bmj.d198 · DOI · Paper page
  6. Driver, 2011, Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case control study, British Medical Journal, 342, d198, 10.1136/bmj.d198 · DOI · Paper page
  7. Etminan, 2006, NSAID use and the risk of Parkinson's disease, Current Drug Safety, 1, 223, 10.2174/157488606777934404 · DOI
  8. Etminan, 2008, Non-steroidal anti-inflammatory drug use and the risk of Parkinson disease: a retrospective cohort study, Journal of Clinical Neuroscience, 15, 576, 10.1016/j.jocn.2007.02.095 · DOI
  9. Gao, 2011, Use of ibuprofen and risk of Parkinson disease, Neurology, 76, 863, 10.1212/WNL.0b013e31820f2d79 · DOI · Paper page
  10. Hancock, 2007, Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease, Archives of Neurology, 64, 576, 10.1001/archneur.64.4.576 · DOI · Paper page
  11. Hernan, 2006, Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease, Neurology, 66, 1097, 10.1212/01.wnl.0000204446.82823.28 · DOI · Paper page
  12. Powers, 2008, Combined effects of smoking, coffee, and NSAIDs on Parkinson's disease risk, Movement Disorders, 23, 88, 10.1002/mds.21782 · DOI · Paper page
  13. Ton, 2006, Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease, Movement Disorders, 21, 964, 10.1002/mds.20856 · DOI · Paper page
  14. Wahner, 2007, Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease, Neurology, 69, 1836, 10.1212/01.wnl.0000279519.99344.ad · DOI · Paper page
  15. Anderson, 1984, Diflunisal in idiopathic Parkinson's disease, Neurology, 34, 400, 10.1212/WNL.34.3.400 · doi:10.1212/wnl.34.3.400
  16. Chen, 2008, Peripheral inflammatory biomarkers and risk of Parkinson's disease, American Journal of Epidemiology, 167, 90, 10.1093/aje/kwm260 · DOI · Paper page
  17. Hakansson, 2007, Cycloxygenase-2 polymorphisms in Parkinson's disease, American Journal of Medical Genetics Part B (Neuropsychiatric Genetics), 144B, 367, 10.1002/ajmg.b.30449 · DOI
  18. Rugbjerg, 2010, Risk for Parkinson's disease among patients with osteoarthritis: a Danish cohort study, Movement Disorders, 25, 2355, 10.1002/mds.23274 · DOI
  19. Wahner, 2007, Inflammatory cytokine gene polymorphisms and increased risk of Parkinson's disease, Archives of Neurology, 64, 836, 10.1001/archneur.64.6.836 · DOI · Paper page
  20. AD2000 Collaborative Group, 2008, Aspirin in Alzheimer's disease (AD2000): a randomised open-label trial, Lancet Neurology, 7, 41, 10.1016/S1474-4422(07)70293-4 · DOI
  21. ADAPT research group, 2006, Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT), PLoS Clinical Trials, 1, e33, 10.1371/journal.pctr.0010033 · DOI · Paper page
  22. Aisen, 2002, Randomized pilot study of nimesulide treatment in Alzheimer's disease, Neurology, 58, 1050, 10.1212/WNL.58.7.1050 · DOI · Paper page
  23. Asanuma, 2007, Common anti-inflammatory drugs are potentially therapeutic for Parkinson's disease?, Experimental Neurology, 206, 172, 10.1016/j.expneurol.2007.05.006 · DOI
  24. Asanuma, 2008, Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinson's disease, Current Pharmaceutical Design, 14, 1428, 10.2174/138161208784480153 · DOI
  25. Breitner, 2009, Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort, Neurology, 72, 1899, 10.1212/WNL.0b013e3181a18691 · DOI · Paper page
  26. Reeves BC Deeks JJ Higgins JPT Wells GA Chapter 13: Including non-randomised studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org. · DOI · Paper page
  27. Davis, 2007, Aspirin and anti-inflammatory drugs for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD006378 · DOI
  28. de-Craen, 2005, Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia, American Journal of Epidemiology, 161, 114, 10.1093/aje/kwi029 · DOI · Paper page
  29. Esposito, 2007, Non-steroidal anti-inflammatory drugs in Parkinson's disease, Experimental Neurology, 205, 295, 10.1016/j.expneurol.2007.02.008 · DOI · Paper page
  30. Etminan, 2003, Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies, BMJ, 327, 128, 10.1136/bmj.327.7407.128 · DOI · Paper page
  31. Klegeris, 2007, Therapeutic approaches to inflammation in neurodegenerative disease, Current Opinion in Neurology, 20, 351, 10.1097/WCO.0b013e3280adc943 · DOI · Paper page
  32. Konstantinopoulos, 2005, The cardiovascular toxicity of selective and nonselective cycloxygenase inhibitors: comparisons, contrasts and aspirin confounding, Journal of Clinical Pharmacology, 45, 742, 10.1177/0091270005278202 · DOI · Paper page
  33. Reines, 2004, Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study, Neurology, 62, 66, 10.1212/WNL.62.1.66 · DOI · Paper page
  34. The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008
  35. Salpeter, 2006, Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs, American Journal of Medicine, 119, 552, 10.1016/j.amjmed.2005.10.056 · DOI
  36. Sandyk, 1985, Acute exacerbation of Parkinson's disease with sulindac, Annals of Neurology, 17, 104, 10.1002/ana.410170124 · DOI
  37. Scharf, 1999, A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease, Neurology, 53, 197, 10.1212/WNL.53.1.197 · DOI · Paper page
  38. Shaunak, 1995, Exacerbation of idiopathic Parkinson's disease by naproxen, BMJ, 311, 422, 10.1136/bmj.311.7002.422b · doi:10.1136/bmj.311.7002.422b
  39. Smith, 2008, Inflammation in Parkinson's disease: an update, Current Opinion in Investigational Drugs, 9, 478
  40. Szekely, 2004, Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic review, Neuroepidemiology, 23, 159, 10.1159/000078501 · DOI · Paper page
  41. Tabet, 2002, Indomethacin for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003673 · DOI · Paper page
  42. Tabet, 2003, Ibuprofen for Alzheimer's disease, Cochrane Database of Systematic Reviews, 10.1002/14651858.CD004031 · DOI
  43. Staa, 2008, What is the harm-benefit ratio of Cox-2 inhibitors?, International Journal of Epidemiology, 37, 405, 10.1093/ije/dym296 · DOI
  44. Wersinger, 2006, An inflammatory pathomechanism for Parkinson's disease?, Current Medicinal Chemistry, 13, 591, 10.2174/092986706776055760 · DOI · Paper page
  45. Whitton, 2007, Inflammation as a causative factor in the aetiology of Parkinson's disease, British Journal of Pharmacology, 150, 963, 10.1038/sj.bjp.0707167 · DOI · Paper page

Cited by

See all 101

Metadata

Authors
Rees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Clarke, C. E., & Ben-Shlomo, Y.
Venue
Cochrane Database of Systematic Reviews
Publisher
Wiley
Published
2011-11-09
Volume
2011
Issue
11
Pages
CD008454-CD008454
ISSN
  • 1361-6137 (ISSN-L)
  • 1465-1858
OpenAlex
W2158835133
Cited by
101
References
8
FWCI
1.83
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. https://app.cochat.ai/papers/10.1002/14651858.cd008454.pub2
The paper
Rees, K., Stowe, R., Patel, S., Ives, N., Breen, K., Clarke, C. E., & Ben-Shlomo, Y. (2011). Non-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studies. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd008454.pub2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.